Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82.1M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
5.06M
-
Shares change
-
+4.83M
-
Total reported value, excl. options
-
$84.5M
-
Value change
-
+$80.7M
-
Number of buys
-
26
-
Price
-
$16.71
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q1 2021
28 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q1 2021.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.06M shares
of 82.1M outstanding shares and own 6.16% of the company stock.
Largest 10 shareholders include Ally Bridge Group (NY) LLC (681K shares), WELLINGTON MANAGEMENT GROUP LLP (579K shares), Logos Global Management LP (550K shares), BVF INC/IL (464K shares), Cormorant Asset Management, LP (459K shares), Point72 Asset Management, L.P. (396K shares), RA CAPITAL MANAGEMENT, L.P. (312K shares), Ghost Tree Capital, LLC (300K shares), Atlas Venture Advisors, Inc. (210K shares), and D. E. Shaw & Co., Inc. (189K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.